|Targets||Src | VEGFR|
|Description||TG 100801 is the prodrug of TG 100572, which is a multi-targeted kinase inhibitor that inhibit select growth factor receptor tyrosine kinases and Src familt kinases. It is currently in a clinical trial as a first in class, VEGFr2 targeting, topically applied compound for the treatment of AMD. It is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies.|
|Synonyms||TG 100801; TG100801; TG-100801|
Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apa...
T338C Src-IN-2, a pyrazolopyrimidine detivative, has been found to be a c-Src T338C kinase inhibitor and could be significant for determing the effect of kinase...
CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...
PP1 is a potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases. It inhibits p56lck (IC50 = 5 nM), p59fynT (...
Anlotinib Dihydrochloride is a novel multi-target tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenic activities, which was designed to ...
AZM475271 is orally Src tyrosine kinase inhibitor with potential anticancer and antimetastatic activities. AZM475271 remarkably inhibits growth and metastasis ...
MCB-613 is a potent steroid receptor coactivator (SRC) stimulator.
Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4.